UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeks UBT251 appeared to have a safe and well-tolerated profile consistent with... slovenia times več »
Več iz medija
Youth Sustainable Development International Summit Launch Ceremony...
slovenia times več »
Ascott Accelerates Vietnam Expansion With Nine Signings in 1H 2026,...
slovenia times več »
WRISE Group Unveils WRISE AI Labs and Appoints Dr. Jeffrey Wu as Group...
slovenia times več »
InMobi Advertising Unveils AI-Powered Cross-Screen and Full-Funnel Solutions...
InMobi's unified intelligence engine delivers 2x revenue growth and a 40% improvement in ROAS, while the expanded InMobi Accelerate and Alliance network... slovenia times več »
RiceField Launches August Campaign as Singapore Prepares to Grade Cooking Oils...
The Singapore brand is encouraging households to look beyond price and habit when choosing cooking oil, as saturated fat accounts for 36% of residents'... slovenia times več »
HiDream.ai Raises RMB 1.5 Billion Series C to Advance Native Omni-modal...
The round brings HiDream.ai's total financing over the past three months to more than RMB 2.1 billion and marks its entry into unicorn status slovenia times več »
Welcome to juju world: Pacific Place x CJ Hendry Unveil Hong Kongs...
slovenia times več »
Pogačar claims fifth Tour de France crown
Cycling superstar Tadej Pogačar (UAE Team Emirates-XRG) has secured a historic fifth Tour de France title, equalling the all-time record held by an elite... slovenia times več »

